Why is Astec Lifescienc falling/rising?

As of 15-Jul, Astec Lifesciences Ltd is currently priced at 922.00, reflecting a decrease of 9.15, or 0.98%. The stock has shown a mixed performance recently, with a 1-week return of +1.75%, outperforming the Sensex, which fell by 1.36%. However, over the past month, the stock has gained 17.08%, while the Sensex has only increased by 1.79%. Despite these short-term gains, the stock has a troubling long-term outlook, with a significant decline of 32.22% over the past year and a staggering 54.61% drop over the last three years. The company has also reported negative results for the last four consecutive quarters, indicating weak operational performance. While there is rising promoter confidence due to a 4.12% increase in their stake, the overall financial health is concerning, highlighted by a negative EBITDA and a high Debt to EBITDA ratio.
In the broader market context, the Pesticides & Agrochemicals sector has gained by 2.36%, indicating a positive trend in the industry, yet Astec Lifesciences has underperformed its sector by 3.34% today. The stock's liquidity remains adequate, with a delivery volume increase of 18.63% against the 5-day average, suggesting some investor interest. However, the company's long-term fundamental weaknesses, including a -212.13% CAGR growth in operating profits over the last five years and a low return on equity, overshadow these short-term gains. The consistent underperformance against the benchmark over the last three years further emphasizes the challenges facing Astec Lifesciences, contributing to its current price decline.